Anotace:
Purpose of theretrospective, present study was to determine whether fecal microbiota transplantation (fMt) from well known, otherwise healthy lean donor dogs could be capable of substituting disease condition from disease to health status, reverting to factory settings and further might improve thelife quality of dogs with several different diseases. Taking into account study design, setting and enrollment (along with accompanying archive data) this clinical trial was conducted between 2011 to 2024 among 1,885 diseased dogs with several different system involvement were treated with fMt at median number of 2 to 6 occasions. To those of solely eligible dogs (with witten owner consent, triage position, without systemic inflammatory respond syndrome orother hazardous condition) were recruited for thestudy. Data were analyzed from March 2011 to June 2024. All fMt interventions from each lean donor (heterologous) were administered either by gastroduodenoscopy (n = 112 into theduodenum) orby rectal enema (n = 1,773 into thecolon). Available cure rates ranged from 41.42% to 93.61% regarding entire enrolled dogs. Forest plot denoted an overall response rate of 76%. Highest cure rates (nearly 94%) were deemed available for gastroentero-dermatological disorders to those of satisfactory clinical recovery for each cases enrolled. Lowest cure rates were observed for endocrinological and cardiovascular disease conditions exhibiting 41 and 47%, respectively. Available results were establishing futuremeta-analysis source inwhich data is lacking. This study should highlighten theefficacy and possible treatment switching modalities to those ofuncurable diseases.